αIIbβ3-Integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells

ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)


Volume 15, 14 Issues, 2014


Download PDF Flyer




Current Drug Targets

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 52nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.597
5 - Year: 3.558

αIIbβ3-Integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells

Author(s): Joanna Kononczuk, Arkadiusz Surazynski, Urszula Czyzewska, Izabela Prokop, Michal Tomczyk, Jerzy Palka and Wojciech Miltyk

Affiliation: Department of Pharmaceutical Analysis, Medical University in Bialystok, ul. Adama Mickiewicza 2D, 15-222 Bialystok, Poland

Abstract

Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the certain cancer cell lines. The molecular mechanism of its action in cancer cells remains unknown. This study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-B and HIF-1, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression of POX, HIF-1, NF-B,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic activity in MCF-7 cells than Abciximab. Results of this study suggest that Eptifibatide may be considered as a novel candidate for development of new anticancer therapy


Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 15
First Page: 1
Page Count: 1
DOI: 10.2174/1389450115666140804220441
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science